Skip to main content
Premium Trial:

Request an Annual Quote

Abaxis, LamdaGen Teaming Up to Combine POC Platform with Plasmon Resonance Biosensing

Premium

Point-of-care device manufacturer Abaxis and biosensor firm LamdaGen said this week that they have entered into an R&D agreement aiming to integrate LamdaGen's plasmonic ELISA technology on Abaxis's rotor-based POC platforms.

If the integration proves viable, the agreement would enable Abaxis to multiplex a variety of markers on its rotor-based system, Abaxis CEO Clint Severson said in a statement.

"Both medical and veterinary customers will be able to simultaneously analyze for chemistry parameters as well as for infectious disease, hormones and a wide range of other markers on the same rotor," he said. "The ability to unify both diagnostic systems
onto our existing rotor will greatly expand Abaxis’ global diagnostic offerings.”

LamdaGen's biosensor platform is based on localized surface plasmon resonance, offering quantitative results and detection levels in the femtomolar range.

Financial and other terms of the agreement were not disclosed.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.